bionaturis

/Tag:bionaturis
­

Bionaturis Group FY-2017 audited results

Highlights

Reports net sales of €2.39 million, +82% YoY
Reports EBITDA of €1.07 million, + €1.50 million YoY
Reports 82% of gross margin over net sales versus 71% in FY-2016
Reports the binding integration agreement with ADL Biopharma to create an European benchmark in the development and manufacturing of biological products
Reports a commercial and supply license agreement of non-prescription products for livestock with minimum annual orders worth of € 4.77 million
Reports the executions of an exclusive license agreement for the development, registration, manufacturing, and commercialization of BNT005 in Argentina and Paraguay.
Reports the signing of an Evaluation and Licensing agreement with exclusive worldwide license rights (except in Argentina and Paraguay) for the development, registration and commercialization of BNT005 with a top leading company in the sector
Reports ZIP patents granted in USA, EUROPE and JAPAN
Reports reaching an E&O agreement with a global leader for the exclusive development, registration and marketing of a probiotic for oral application, indicated to improve oral health in companion animals
Reports the signing by Biobide of new relevant contracts with three leading companies in the agrochemical and biomedicine sectors, for a cumulative amount worth of USD 1.39 million
Reports BNT005 patent granted in CHINA

 Click here to see the official document.

April 27th, 2018|Blog english|Comments Off on Bionaturis Group FY-2017 audited results

New Events Calendar

April 23rd, 2018|Blog english|Comments Off on New Events Calendar

Bionaturis Group gets patent approval in India

Bionaturis Group has received notification from the patent office of India of the approval of the patent entitled “Production of biologically active proteins”, contributing to the protection of this patent family, already approved in the main European markets, USA, China, Mexico, Canada, and Australia.

Specifically, this patent family protects the production and use, within the pharmacological field, of ZERA-based microparticles, a self-assembling sequence developed by ZIP. These microparticles have demonstrated efficacy as second-generation vaccines, being able to develop a higher immune response than the same antigen in soluble form and without using of additional adjuvants. ZERA VACCINES are currently being evaluated by leading companies in the veterinary sector in order to formalize licensing agreements.
Zera Vaccines is part of the technological portfolio of the CDMO division of the biotechnological group, provided by ZIP Solutions, a specialist in bioprocesses at industrial scale.

Bionaturis Group, which is integrating businesses with ADL Biopharma, has received up to four patent approvals year to date, strengthening the protection of its high-tech premium portfolio. Please, click here to read the Relevant Information (only in Spanish)
 

April 11th, 2018|Hechos Relevantes|Comments Off on Bionaturis Group gets patent approval in India

Splittera patent also granted in Israel

Bionaturis Group has received notification from the patent office of Israel of the approval of the patent entitled “Split inteins and uses thereof”, contributing to the protection of the Splittera system, joining to the already granted in the main European markets, China, Japan, and Australia.

This patent family is of special relevance for Bionaturis group since Splittera is subject of a worldwide exclusive licensing agreement with a top leading multinational company, for its commercialization in the industrial purification of biological products. The agreement contemplates upfront, milestone-payments and royalties for sales. This agreement is a proof of principle of the usefulness and added value of Splittera for the biopharmaceutical sector, which presents a global expected market figure worth of 236 billion dollars by 2019.
Splittera is part of the technological portfolio of the CDMO division of the biotechnological group, provided by ZIP Solutions, a specialist in bioprocesses at industrial scale.Please, click here to read the Relevant Information (only in Spanish)

April 4th, 2018|Blog english|Comments Off on Splittera patent also granted in Israel

The presence of Bionaturis at BioEurope Spring

 

 

From March 12 to 15, Bionaturis Group has attended ‘Bio Europe Spring ‘, one of the most important biotechnology event in Europe, hold this edition at the Amsterdam’s Convention Center. Juan Jose Infante, Chief of Biological developments at Bionaturis Group and one of our representatives at the event, tells us about his main remarks and outcomes.

 

 

1. BIOEUROPE SPRING is an event that, for some days, brings together hundreds of the world’s most innovative leaders across biotech, finance and pharma for high-level networking, pre-scheduled partnering meetings, strategic panel discussions and more. What do you think that Bionaturis Group has to offer differentially to those attending the event?

Biotechnology is a field that evolves to a dizzy speed. Breakthrough innovations that will feed the healthcare sector in the following years are cooked mainly in the R&D departments of SMEs. It is a high volatile world and there is a need for agile management practices. Unlike big multinationals, Bionaturis can go as nimble as the rapidly shifting and unpredictable context in which the sector find itselfe. Bionaturis, after 11 years developing innovative premium products, has now enough maturity to be a partner of choice for agile movements to the marketplace. Thus, what third parties expect from us in these events is the right partner to bring innovative products to the market in a practical and agile way.

2. It is the first time that Bionaturis Group has attended this event after announcing the integration agreement with ADL Biopharma, a turning point for the company. How have you perceived the reception of this news in the sector?

As good as it gets! It is the right time to offer a proposal as the one derived from the integration between Bionaturis and ADL […]

March 21st, 2018|Blog english|Comments Off on The presence of Bionaturis at BioEurope Spring

Zip patent of Bionaturis Group granted in Australia

ZIP Solutions is a biotechnological company devoted to develop and commercialise innovative solutions for industrial and pharmaceutical applications. The company has an in-depth knowledge of the requirements of the human and animal health industry, and offers its proprietary solutions, Zera® and Splittera, as differentiating and highly competitive tools to meet their demanding needs. 

 

These patents are of special relevance for Bionaturis group since Splittera is subject of a worldwide exclusive licensing agreement with a top leading multinational company, for its commercialization in the industrial purification of biological products. The agreement contemplates upfront, milestone-payments and royalties for sales. This agreement is a proof of principle of the usefulness and added value of Splittera for the biopharmaceutical sector, which presents a global expected market figure worth of 236 billion dollars by 2019.
Splittera is part of the technological portfolio of the CDMO division of the biotechnological group, provided by ZIP Solutions, a specialist in industrial bioprocessing.

To read the Relevant Information (only in Spanish) click here.

About Bionaturis

Bionaturis Group offers premium solutions for human and animal health; it comprises four companies (Bionaturis, Biobide, ZIP Solutions, and BNT Pacific) and two subsidiaries (Biobide USA and BNT China Biosciences) in six different locations around the world. Bionaturis lists on the Spanish stock exchange for SMEs (trading code BNT).

 

 

March 8th, 2018|Blog english|Comments Off on Zip patent of Bionaturis Group granted in Australia

Fran Bascón tells us about VIV-MEA 2018,Abu Dhabi.

         Last 5th and 6th of February, Bionaturis was present at VIV-MEA , the most important animal health evento of the EMA region.

 

Abu Dhabi turned for a few days into a neuralgic animal health center for production animals  for the Middle East and Africa.

Our sales manager, Fran Bascon, event assistant, tells us first-hand impressions.

 

 

1. VIV-MEA is an event indexes in animal health for the zone that concentrates visitors and companies from many countries and places of the world. Which were the aims of the Group Bionaturis in this event?

Our attendance to the event has been a great opportunity for 1) gaining more knowledge and insights of the market in Middle East, 2) consolidate the strategic relations we already have in the territory and 3) finding new synergies. Middle East is a huge market that is demanding and consuming innovative products at a very fast pace (for instance, the use of probiotics for animal feed has grown 600% in the past 5 years). Products with a strong scientific background and a solid development are highly desired and in that sense, Bionaturis has a lot to value to deliver.

In terms of number of European companies in the event, the attendance has been pretty significant. Despite the fact that there is a homologous event in Europe, all the big players were in the event, thus highlighting the importance of this region and the opportunity of entering in that market.

 

2. During the day, took place events about networking  and you had the possibility of meeting several companies from the region, how you value the VIV-MEA event as forum to find new opportunities of business?

The event was the perfect environment to gain first-hand experience of the market in Middle East, their challenges […]

February 21st, 2018|Blog english|Comments Off on Fran Bascón tells us about VIV-MEA 2018,Abu Dhabi.

Bionaturis Leishmaniasis Vaccine Granted in USA

 

This new concession in USA joins the one already obtained by Bionaturis in China last September for the same patent family.

 

Each year 80 million dogs are in danger of developing the disease in the affected areas of Europe and America. Visceral leishmaniasis affects more than 700,000 people worldwide each year, with the dog being the main reservoir of the disease.

 

The granted patent protects the use of the intended vaccine in dogs and humans.

 

Bionaturis goes one step further in the pet market, which according to Euromonitor International represented 93,000 million euros in 2015.

 

The Centro de Desarrollo Tecnologico e Industrial (CDTI) has also granted Bionaturis a non-refundable incentive worth 196,300 euros to support the achievement of a new intermediate milestone in the development of the vaccine.

 

Jerez de la Frontera, February XX, 2018.- The US Patent and Trademark Office (USPTO) has granted the patent for the prevention and treatment of visceral leishmaniasis in both dogs and humans to the vaccine against this disease, which Bionaturis holds the worldwide exclusivity. The lead vaccine program, called internally BNT005, comes originally from the CSIC (Spanish National Council of Research)

 

Currently, BNT005 is the subject of an Evaluation and Options (E&O) agreement with an international sponsor for the exclusive sublicense of the registration and commercialization of BNT005 for use in dogs worldwide, except Argentina and Paraguay, where it has been already licensed for the same purpose to the Argentine laboratory Biotandil.

 

Visceral leishmaniasis affects between 700,000 and 1,000,000 people each year and has a mortality rate of 3%, according to data provided by the World Health Organization (WHO). In Spain, it is estimated that around 300 people suffer each year. It is a tropical disease that is transmitted through the bite of insects. The […]

February 21st, 2018|Blog english, Hechos Relevantes|Comments Off on Bionaturis Leishmaniasis Vaccine Granted in USA

Bionaturis Signs Binding Agreement With ADL For Integration Operation

• Bionaturis and ADL Biopharma will create a European biotechnological benchmark.
• The integration operation is subject to the pertinent approvals.
• After the integration, a capital increase is planned to enhance the free-float, the liquidity of the shares and to finance the growth of the integrated company
• Black Toro Capital, the fully owners of ADL Biopharma, will control 85% of the resulting company.

Bionaturis (ticker BNT) have just signed a binding integration agreement with ADL Biopharma, a company specialized in industrial bioprocessing of fermentation-based products with applications in human and animal health.This integration agreement aims to build-up a European leader in red biotechnology, focused mainly on the development and commercialization of high-value fermentation-based bioproducts.Bionaturis will add its capacity to develop premium products and its position as a reference partner of the One Health concept, and ADL will contribute with one of the biggest fermentation sites in Europe and with a broad customer portfolio. The integration will produce many synergies for both companies, highlighting the level of complementarity of their customers and products. The resulting company will offer a broader spectrum of products and services, covering different features and needs of the steady growing human and animal health sectors.

Pilar de la Huerta, CEO of ADL Biopharma, has stated: “Bionaturis innovation capacity along with the industrial capacity of ADL will expand quickly our products and market opportunities, enhancing our growth significantly, and positioning the integrated company as a leader in Southern Europe in the development and production of fermentation bioproducts for human and animal applications”.

For Victor Infante, CEO of Bionaturis Group, as a reference partner in the One Health concept the operation “will increase our customer base, expand the industrial production capacity of our premium products and will enhance our innovation in the fields of human and animal health. The new structure will help us optimize the […]

December 4th, 2017|Blog english, Hechos Relevantes|Comments Off on Bionaturis Signs Binding Agreement With ADL For Integration Operation

Bionaturis reports a supply contract worth of €4,77 million/year

· The animal health division of Bionaturis Group has signed a license agreement for the supply and distribution of non-prescription products for livestock with minimum annual orders worth of € 4.77 million

· The products subject of the contract are intended to lead to a more rational use of antibiotics in livestock

· The signing of this contract joins the uptrend of significant organic growth that every divisions of the group is performing

Jerez de la Frontera, November 16, 2017.

 

Bionaturis Group has reported that its animal health division has signed a license agreement for the exclusive registration and commercialization of non-prescription products for food production animals (FPAs) with an international client of regional scope. Under the license agreement, Bionaturis will supply the products and technical assistance, while the client will be in charge of importing, distributing and selling them, as well as obtaining the marketing authorization, whose ownership will be shared. The supply agreement has an initial term of three years with automatic renewal of one-year periods and a minimum annual order commitment of €4.77 million euros, once the marketing authorization has been obtained, estimated for the second quarter of 2018.

The products subject of the contract are intended to lead to a more rational use of antibiotics in livestock farms, one of the cornerstones of the One Health concept “one world, one health”, that summarizes an idea that had been known for more than a century; that human health and animal health are interdependent and bound to the health of the ecosystems in which they exist. According to the OIE – World Organization for Animal Health, 60% of known human infectious diseases are zoonotic (domestic or wild animals), as well as 75% of emerging human diseases have animal […]

November 16th, 2017|Blog english|Comments Off on Bionaturis reports a supply contract worth of €4,77 million/year

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.

CERRAR